cyrilzakka/clinical-trials huggingface dataset:
Accuracy of FNA Versus CNB of Abnormal Axillary Lymph Nodes in Setting of Invasive Breast Cancer

To compare accuracy of ultrasound guided fine needle aspiration (FNA) to core needle biopsy (CNB) of ultrasound detected abnormal axillary lymph nodes in patients with newly diagnosed invasive breast cancer or suspected invasive breast cancer.

Hypothesis: FNA and CNB have equivalent diagnostic accuracies

In order to prove our hypothesis, we will perform FNA and CNB on the same lymph node in each consented patient. The two samples will be evaluated separately by different pathologists blinded to the material in the other sample.

The results of the biopsies will be compared to the gold standard (lymph node excision).


Eligibility Criteria:
Inclusion Criteria:

* Recent or suspected diagnosis of invasive breast cancer with abnormal ipsilateral axillary lymph node
* Able to provide informed consent

Exclusion Criteria:

* Lymph node not amenable to core biopsy
* Patient is unlikely to undergo lymph node excision (i.e. elderly patient with co-morbidities)
Knowledge, Attitude and Practice Regarding Caries Risk Assessment for Children and Adults Among Dental Residents

Evaluation of knowledge, practice and attitude regarding Caries Risk Assessment for children and adults among Dental Residents in Faculty of Dentistry, Cairo University.

Dental caries is a dynamic and multifactorial process. Occurrence of dental caries is affected by several factors including quantity and composition of saliva, oral microflora and patient-related parameters including general health and lifestyle, such as the use of fluoride-containing toothpastes and diet.

Caries risk is defined as the probability of developing caries in the future. The incidence of the disease can be either primary (New caries lesions) or secondary (Progression of lesion or reactivation of caries lesions). Caries risk assessment (CRA) is important for the successful application of a minimum intervention dentistry philosophy in the management of dental caries. Patients, with active caries at the time of visit, need the CRA to identify the factors that are most likely to progress in the disease process. The CRA is one of the methods for managing the caries of patients.

Riley et al. showed that the anti-caries agents were widely used in dental clinics, while the CRA was performed by a few dental clinics. In a study of Gaskin et al., 63.5% of subjects agreed with the use of minimal intervention dentistry. In a study of Shah et al., 36% of dentists accepted the use of restorative materials and CRA-based methods, and 15.5% also strongly agreed with CRA for all patients. In a study by Rayapudi and Usha, 81% of participants agreed with CRA in patients. In a study by Riley et al. about the use of CRA by dentists in children, 73% of dentists reported having CRAs for people aged 6 to 18 years. In another study by Riley et al., 69% of dentists performed CRA for patients, and 57% of dentists who performed CRA had considered an individualized caries prevention programs for their patients. Hurlbutt et al. showed that caries management by the CRA is an example of patient care that has the best practice rather than traditional therapies.

Afshar et al. claimed that the CRA is a conservative approach that can prevent waste of time, energy and finances. Evaluating the management of the results of illness in certain periods of time leads to less dental tissues wasting. People's knowledge of CRA in patients leads to more conservative treatment. Due to limited studies in this field and the absence of data about using CRA in Egypt, Especially on dental residents, this study was conducted to evaluate the knowledge, attitude and practice regarding Caries Risk Assessment among pediatric and Conservative Dental Residents in Faculty of Oral and Dental Medicine, Cairo University.

Eligibility Criteria:
Inclusion Criteria:

* Pediatric and conservative dental residents in Faculty of Dentistry, Cairo University.

Completing at least 3 months residency program in one of the departments

Exclusion Criteria:

* Participants who refuse to participate.
Heat Therapy and Muscle Function Study

Exercise tolerance decreases with age and a sedentary lifestyle. Muscle critical power (CP), is a sensitive measure of exercise tolerance that is more even more relevant to and predictive of endurance performance than VO2max.

While recent evidence indicates that CP and muscle function decrease with aging, the cause of this decrease in CP and the best way to mitigate the decrease in CP are unknown.

This study will:

1. Measure knee extensor CP in young and old individuals and determine the extent to which changes in muscle oxygen delivery (e.g. resistance artery function, maximum exercise blood flow), muscle mass and composition (e.g. whole-muscle size, muscle fiber cross-sectional area) and mitochondrial oxygen consumption (e.g. maximal coupled respiration of permeabilized fibers biopsied from the knee extensors) contribute to the decrease in CP with age.
2. Examine the effectiveness of two different therapies (1. High Intensity Interval Training, HIIT and 2. Muscle Heat Therapy) at improving muscle function and critical power in young and older adults.
3. Examine the impact of muscle disuse (2 weeks of leg immobilization), a potential contributor to the decrease in muscle function with aging, on muscle function and critical power and determine if heat therapy is an effective means of minimizing the impact of disuse on muscle function and critical power.


Eligibility Criteria:
Inclusion Criteria:

* 18-95 years of age
* Currently no cardiovascular or metabolic disease (e.g. heart failure, diabetes)
* ability to perform knee extension exercise

Exclusion Criteria:

* Pregnant
* Current cardiovascular or metabolic disease (e.g. heart failure, diabetes)
* participating in exercise training within the last 6 months
* inability to perform knee extension exercise
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding returning of genomic results on participants' health and satisfaction. Participants in this study will be presented with the choice of types of genomic results to receive, and the Engagement Optimization Unit (EOU) will investigate the impact of this intervention on participant knowledge, expectations of benefit, personal utility, and decisional conflict.


Eligibility Criteria:
Eligibility Criteria:

* Patients with cholangiocarcinoma, multiple myeloma, or early onset colon or rectal cancer.

  * If diagnosed with multiple myeloma, must be African-American.
  * If diagnosed with colon or rectal cancer, must be African-American AND must be no older than 65 years old at the time of diagnosis.
  * At least 18 years old
  * Able to understand and willing to sign an IRB-approved written informed consent document
Ingrown Toenails : Surgery Only Versus Surgery + Chemical Cauterization With TCA

Ingrown toenail is a very common disease in the general population that touches young adults. There are lots of treatments from local care of pedicure to surgery with matricectomy. Gold standard of symptomatic and painful ingrown toenail is the simple surgery with matricectomy and with suture or directed healing pad.

For many years chemical cauterisation with phenolic acid is used, a method with very few relapses and with a more simple pad. However, because of a lack of information about this phenolic acid, the pharmaceutical laboratory withdrew it from the market.

The new method to replace phenolic acid is trichloroacetic acid, used mainly in cosmetics for peeling. This method was already compared to phenolic acid and showed equal results with fewer laps of application and a low cost. The comparison between acid trichloroacetic method and the gold standard surgery was never done and will be the goal of this study.

It's an open, non randomised, comparative, multicentric (2 centers) study with two groups : common surgery and surgery with chemical cauterisation For this study the investigators will compare between the two groups : gain of quality of life at one month after surgery, difference of pain between before, one week and one month after surgery, the occurrence of adverse events and number of relapses at one year.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of ingrown toenail
* Patient informed and with signed informed consent

Exclusion Criteria:

* Medical history of ingrown toenail on the concerned nail
* Other nail disease
* Pregnancy
* Allergy to local anesthetic or to trichloroacetic acid
Observing the Changes of Endocrine and Metabolism in Patients With Thalassemia Major

Patient with thalassemia major have many endocrine diseases, such as hypopituitarism, hypothyroidism, hypoparathyroidis, osteoporosis, and etc.. These problems may be due to anemia itself or related to iron deposition. This study aimed to investigate the endocrine aspect of thalassemia major patients in Taiwan in order to introduce early intervention or treatment in the future.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of Thalassemia major
* Patients of 20-85 years old

Exclusion Criteria:

* Patients younger than 20 years old.
* Patients older than 85 years old.
* Patients who are pregnant
Impact of Systematic Nursing Orientations in the Reduction of Predicted Cardiovascular Risk in Patients With Coronary Artery Disease.

Evaluate the impact of systematic nursing orientations in the reduction of predicted cardiovascular risk in patients with coronary artery disease during four nursing visits for a 1-year period and compare to a group of patients submitted to conventional treatment.

Assess 184 (two groups) patients during four nursing visits for a 1-year period and compare to a group of patients submitted to conventional treatment. We will evaluate the impact of systematic nursing orientations in the reduction of predicted cardiovascular risk in patients with coronary artery disease.

Eligibility Criteria:
Inclusion Criteria:

* patients of both sexes;
* aged 18 years or older;
* diagnosed with ACS (unstable angina and acute myocardial infarction with ST segment elevation and without ST segment elevation) with CAD diagnosed by cardiac catheterization or electrocardiogram;
* patients have to agree to participate by signing a consent term

Exclusion Criteria:

* patients with cognitive deficits;
* neurological sequelae;
* who are not able to come for visits, or who do not consent to participate in the study.
A Study to Evaluate the Safety and Efficacy of Product X92001327 vs RID Shampoo in Subjects With Head Lice

The purpose of this study is to compare the efficacy and safety of an insecticide-free head lice product with that of a pyrethrum-based product.

The primary objective of the study was to compare the safety and efficacy of X92001327 versus RID in subjects with head lice. The subjects received a single application on Day 0 of either X92001327 or RID shampoo based on the randomization schedule. A repeat application of the test product was administered on Day 7. Subjects visited the clinic four times: on Day 0, Day 1, Day 7 and Day 10.

Eligibility Criteria:
Inclusion Criteria:

* Male or female over the age of 1 at the time of signing the informed consent or giving assent
* Have an active head lice infestation of at least 5 live lice and 5 viable nits
* subject must be capable of understanding and providing written informed consent
* agree not to use any other pediculicides or medicated hair grooming products for the duration of the study
* agree not to use a lice comb during the study
* the parent or guardian of a child must be willing to have other family members screened for head lice.
* have a single place of residence

Exclusion Criteria:

* used any form of head lice treatment whether prescription or over the counter or home remedy at least four weeks prior to their screening visit
* used any topical medication of any kind for a period of 48 hours prior to the screening visit
* individuals on systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel may interfere with the study results
* has a history of allergy or hypersensitivity to ragweed, hydrocarbons, sesame oil, perfume or any ingredient in either test product
* individuals with any visible skin/scalp condition at the treatment site which, in the opinion of the investigative personnel will interfere with the evaluation of the test product
* individuals who, in the opinion of the investigative personnel do not understand the subject requirements for study participation and/or may be likely to exhibit poor compliance with the required visits
* females who are pregnant or nursing
* patients that have taken trimethoprim or a combination of sulfamethoxazole at evaluation or during the previous 4 weeks
* subjects with hair longer than mid back
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic

The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.

Participants will receive six injections of Dupixent or placebo (two 300 mg loading doses and one 300 mg dose every two weeks after that).

In addition, participants will be asked to complete questionnaires to determine daily itch severity, quality of life, treatment benefit, physical functioning, and pain interference.

Individual participants will require 13 weeks to complete all study visits.

Eligibility Criteria:
Inclusion Criteria:

• Persons 18-60 year old with post-burn hypertrophic scars of any size which required grafting or epidermal autografting for an acute burn injury, with continued complaint of pruritus due to inadequate relief from standard of care (medical management by antihistamine and neuroleptic medications) after at least four weeks and are a minimum of four weeks after their last grafting surgery, and who speak English sufficient to participate in the study.

Exclusion Criteria:

* Currently taking Dupixent for any other diagnosis
* known allergy to Dupixent
* pregnant and or lactating mothers
* anyone treated for pruritus using laser therapy
* currently receiving adequate relief for pruritis under standard of care medical management by antihistamine or neuroleptic medications
* Currently taking steroids
* persons with developmental delays or otherwise unable to complete measures
* prisoners or anyone otherwise unable to give their own consent or who is not their own guardian
* one or more of the following existing disorders: conjunctivitis; any co-existing dermatological condition except burns; any type of cancer; requiring dialysis; chronic Stage 3 or higher kidney disease; biliary disorder; gall bladder disorder; or another renal or hepatic disorder which, in the opinion of study physician, deems this study inappropriate for an eligible individual.
* Persons unable to provide their own consent, including prisoners when their incarcerated status is not itself the focus of study, are routinely excluded from clinical trials at this site
* We further exclude persons with other dermatological conditions (other than burn) , which may have pruritis or pain associated with them and who may be treated with medications other than Dupixent, and whose perceived benefit could confound our results.
* We similarly exclude anyone treated for pruritis by laser therapy as their perceived benefit could confound our results.
Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy

To assess the efficacy of pregabalin compared to placebo on pain following hysterectomy , measured using subject reported assessments of pain.


Eligibility Criteria:
Inclusion Criteria:

* The subject will have elective total abdominal hysterectomy using a transverse incision with or without bilateral salpingo-oophorectomy. The total hysterectomy may, however, be cervix-sparing.
* The subject is expected to remain at the hospital (or intermediate care facility) for a minimum of 2 days following surgery.
* The subject's preoperative health is graded as the American Society of Anesthesiologist P1 to P2.

Exclusion Criteria:

* Subjects having vaginal hysterectomy (whether laparoscopically assisted or not)
* Subjects having additional procedures (such as those involving the bladder) at the same time as the total abdominal hysterectomy
* The use of nerve block, spinal anesthesia or epidural anesthesia for post-surgical pain control
* Subjects who have been using any opioid medications 2 weeks or more continuously within 3 months prior to the screening visit.
* The subject has taken any NSAID or any analgesic other than acetaminophen within 3 days prior to surgery or is unwilling to abstain from NSAIDs or other analgesics, except as specified in the protocol, during the study. (Subjects taking \<325 mg per day of aspirin at a stable dose for at least 30 days before the first dose of study medication will be allowed to continue their aspirin regimen for the duration of the study).
Transition From Donor Milk: a Feasibility Study

Preterm and very low birth weight (VLBW, \< 1,500g) infants who receive donor human milk (DHM) often experience slow postnatal growth and no clinical data is available to guide the duration of DHM for preterm infants. We hypothesize that transitioning from DHM to preterm infant formula after the first month of life is both safe and conveys improved weight and length gains and fat free mass accumulation.


Eligibility Criteria:
Inclusion Criteria:

1. Greater than 1,250 grams
2. At least 28 days of life
3. Diet consisting of donor human milk with/without mother's own milk

Exclusion Criteria:

1. Birth weight below the 5th percentile
2. History of necrotizing enterocolitis, spontaneous intestinal perforation, or other gastrointestinal disorder
3. Congenital anomalies
4. Care team discretion
Hearing Aid Signal Processing Comparative Study

Participants will be fit with each of two hearing instruments in an ABA cross-over design. The study will consist of a total of three approximately 10-day home trials with the devices. Participants will be asked to provide qualitative feedback to investigators regarding the performance of and their preference for each hearing instrument.


Eligibility Criteria:
Inclusion Criteria:

* Moderate to severe sensorineural hearing loss
* Current hearing aid user

Exclusion Criteria:

* Lack of willingness to wear study devices for approximately one month
* Inability to travel to study appointments or to complete questionnaires.
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Neoadjuvant immunotherapy has become the standard perioperative treatment in lung cancer, but its effective predictive biomarkers are lacking. A small cohort reported that homologous recombination deficiency (HRD) can be used as a reliable biomarker to predict the efficacy of neoadjuvant immunotherapy, but the findings need to be validated in larger cohorts. Moreover, circulating tumor DNA (ctDNA) has the potential to predict the therapeutic efficacy of neoadjuvant immunotherapy.

This study intends to prospectively collect patients with driver-negative stage II-IIIB NSCLC who are scheduled to receive neoadjuvant immunotherapy and surgical resection and verify the value of HRD in predicting the efficacy of neoadjuvant immunotherapy. Meanwhile, the blood samples before and after neoadjuvant immunotherapy were collected for high-depth ctDNA detection to explore the correlation between the dynamic changes of ctDNA and the efficacy and prognosis of neoadjuvant immunotherapy.


Eligibility Criteria:
Inclusion Criteria:

* Stage II-IIIB NSCLC
* EGFR/ALK negative
* The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up

Exclusion Criteria:

* A history of other malignancies within the past 5 years
* Patients with autoimmune disease are not suitable for PD1 monoclonal antibody therapy
Colon Cancer Prevention Using Selenium

Selenium's ability to prevent colorectal cancer (CRC) has been suspected for nearly 30 years, but has never been directly studied in humans. The investigators will directly assess selenium's ability to prevent CRC by measuring alterations in aberrant crypt foci (ACF), an accepted surrogate marker for CRC.

ACF's are very small (i.e., microscopic) collections of abnormally shaped cells that are a commonly used marker of CRC risk. Screening colonoscopy at UIC routinely uses methods that allow ACF counting to be done as a part of standard practice. ACF's are not fixed, like polyps or cancers, but can disappear as a person's risk for developing CRC decreases.

The investigators propose giving patient's with 6 or more ACF's 200 mcg selenized yeast or placebo, and determining if there is a drug-dependant decrease in ACF number. The primary objective is to determine whether selenized yeast supplementation, compared to placebo, causes significant reduction of ACF number from baseline levels. The primary endpoint will be change in ACF number


Eligibility Criteria:
Inclusion Criteria:

- All non-pregnant patients \>50 years of age

Exclusion Criteria:

* The following will be specifically looked for, and result in patients not being eligible for study enrollment:

  * Use of non-steroidal anti-inflammatory drugs or glucocorticosteroids within 60 days of study entry.
  * History of chronic IBD or prior pelvic radiation (inflammation distorts crypt pattern).
  * Intake of any selenium supplements within 60 days of study entry, including vitamins.
  * Patients with increased bleeding risk from biopsy protocol (i.e. renal failure, decompensated cirrhosis, blood dyscrasia).
Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying

The purposes of this study are to determine whether an experimental drug known as tadalafil can reduce symptoms of dyspepsia (fullness after eating, inability to finish a regular meal, bloating, discomfort or pain in the upper abdomen, belching after meals, nausea, vomiting) in diabetic patients, and/or reduce the amount of time the stomach takes to empty the contents of a standard meal. The safety of tadalafil given once daily for 8 weeks in this population will also be studied.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of diabetes mellitus
* Delayed gastric emptying
* 3 month minimum history of chronic upper abdominal discomfort
* Symptoms of dyspepsia (upset stomach)

Exclusion Criteria:

* Major gastrointestinal surgery or medical conditions known to affect gastric motility
* Irritable Bowl Syndrome
* Medications known to affect gastric motility
* Angina treated with nitrates
* Uncontrolled diabetes mellitus and history of certain heart problems